86 related articles for article (PubMed ID: 23763533)
1. A generalized health economic and outcomes research model for the evaluation of companion diagnostics and targeted therapies.
Lee J; Tollefson E; Daly M; Kielb E
Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):361-70. PubMed ID: 23763533
[TBL] [Abstract][Full Text] [Related]
2. [Health care expenditures linked to the use of targeted therapies and diagnostic tests for cancer patients].
Marino P; Bertucci F; Gonçalves A; Seror V
Med Sci (Paris); 2012 Mar; 28 Spec No 1():19-23. PubMed ID: 22494652
[TBL] [Abstract][Full Text] [Related]
3. Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.
Doble B; Tan M; Harris A; Lorgelly P
Expert Rev Mol Diagn; 2015 Feb; 15(2):235-54. PubMed ID: 25142227
[TBL] [Abstract][Full Text] [Related]
4. Interpreting the economic literature in oncology.
Grusenmeyer PA; Wong YN
J Clin Oncol; 2007 Jan; 25(2):196-202. PubMed ID: 17210940
[TBL] [Abstract][Full Text] [Related]
5. Treating in the dark: unanswered questions on costs and benefits of late line therapy for metastatic breast cancer.
Anders CK; Peppercorn J
Cancer Invest; 2009 Jan; 27(1):13-6. PubMed ID: 19160108
[No Abstract] [Full Text] [Related]
6. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
Seo MK; Cairns J
BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Lux MP; Wöckel A; Benedict A; Buchholz S; Kreif N; Harbeck N; Kreienberg R; Kaufmann M; Beckmann MW; Jonat W; Hadji P; Distler W; Raab G; Tesch H; Weyers G; Possinger K; Schneeweiss A
Onkologie; 2010; 33(4):155-66. PubMed ID: 20389141
[TBL] [Abstract][Full Text] [Related]
8. Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer.
Seo MK; Cairns J
PLoS One; 2018; 13(9):e0204496. PubMed ID: 30256829
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.
Borovicka JH; Calahan C; Gandhi M; Abraham TS; Kwasny MJ; Haley AC; West DP; Lacouture ME
Arch Dermatol; 2011 Dec; 147(12):1403-9. PubMed ID: 22184762
[TBL] [Abstract][Full Text] [Related]
11. Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic.
Kelly RJ; Forde PM; Elnahal SM; Forastiere AA; Rosner GL; Smith TJ
J Oncol Pract; 2015 Jul; 11(4):308-12. PubMed ID: 26015459
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
Blank PR; Schwenkglenks M; Moch H; Szucs TD
Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
[TBL] [Abstract][Full Text] [Related]
16. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.
Lee JA; Shaheen M; Walke T; Daly M
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):325-41. PubMed ID: 21671702
[TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer drugs market.
Cassidy S; Syed BA
Nat Rev Drug Discov; 2017 Aug; 16(8):525-526. PubMed ID: 28529321
[No Abstract] [Full Text] [Related]
18. Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment.
Hsu JC; Lin JY; Lin PC; Lee YC
PLoS One; 2019; 14(12):e0225938. PubMed ID: 31830075
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
20. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]